Rein Therapeutics Inc (RNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,055 | -7,113 | -15,732 | -8,393 | -6,566 |
| Depreciation Amortization | 63 | 59 | 151 | -89 | -100 |
| Accounts payable and accrued liabilities | -408 | 966 | -4,982 | -1,236 | -1,584 |
| Other Working Capital | 1,856 | 1,633 | -5,381 | -1,829 | -1,818 |
| Other Operating Activity | 884 | -816 | 6,136 | 2,130 | 2,291 |
| Operating Cash Flow | $-13,660 | $-5,271 | $-19,808 | $-9,417 | $-7,777 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | 42 | 42 | N/A |
| Net Acquisitions | N/A | N/A | -96 | N/A | N/A |
| Sale Of Investment | N/A | N/A | 16,250 | 16,250 | 15,750 |
| Investing Cash Flow | $N/A | $N/A | $16,196 | $16,292 | $15,750 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 15,794 | N/A | N/A |
| Common Stock Issued | 18,263 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $18,263 | $N/A | $15,794 | $N/A | $N/A |
| Exchange Rate Effect | 1 | N/A | -63 | N/A | N/A |
| Beginning Cash Position | 17,338 | 17,338 | 5,219 | 5,219 | 5,219 |
| End Cash Position | 21,942 | 12,067 | 17,338 | 12,094 | 13,192 |
| Net Cash Flow | $4,604 | $-5,271 | $12,119 | $6,875 | $7,973 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,660 | -5,271 | -19,808 | -9,417 | -7,777 |
| Free Cash Flow | -13,660 | -5,271 | -19,808 | -9,417 | -7,777 |